Puxitatug samrotecan
Puxitatug samrotecan is a B7-H4 ADC targeting a checkpoint-like protein enriched in breast, ovarian, and endometrial cancers.
AstraZeneca's B7-H4 ADC in phase 2 (endometrial, ovarian, TNBC). B7-H4 has minimal normal expression and is inversely correlated with PD-L1, offering a route into 'cold' tumours.
Puxitatug samrotecan carries a camptothecin-derived TOP1 inhibitor; exatecan shown as the class representative.
1.Antibody binds B7-H4 on the tumour cell surface
- Route
- IV infusion
- Schedule
- Phase 2 dose-optimisation; every 3 weeks
Source: clinicaltrials.gov/study/NCT05123482. Doses are for orientation; the current label governs.
| Adverse event |
|---|
| Nausea |
| Neutropenia |
| Fatigue |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational | not disclosed | — |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Puxitatug samrotecan" OR ABSTRACT:"Puxitatug samrotecan" OR TITLE:"AZD8205" OR ABSTRACT:"AZD8205") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Puxitatug samrotecan, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductTilatamig samrotecan
Shares Exatecan (and derivatives), Topoisomerase-I inhibitor payloads, AstraZeneca.
- CompanyMersana Therapeutics
Shares Endometrial cancer, Ovarian cancer, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- ProductAK146D1
Shares Exatecan (and derivatives), Topoisomerase-I inhibitor payloads, Triple-negative breast cancer (TNBC).
- TrialRAINFOL-01 (Rina-S)
Shares Endometrial cancer, Ovarian cancer, Antibody-drug conjugate (ADC).
- CompanyCelldex Therapeutics
Shares Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- ProductLuveltamab tazevibulin
Shares Endometrial cancer, Ovarian cancer, Antibody-drug conjugate (ADC).
- ProductMoxetumomab pasudotox
Shares AstraZeneca, Antibody-drug conjugate (ADC).
- TermT030 (belotecan derivative)
Shares Topoisomerase-I inhibitor payloads, Antibody-drug conjugate (ADC).